Completed PHASE3 NCT03568331

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)

A Randomized, Double-Blind, Placebo-Controlled Efficacy Study of The Neurokinin-1 Receptor Antagonist VLY-686 in Patients With Atopic Dermatitis

Sponsor: Vanda Pharmaceuticals

Conditions Atopic Dermatitis

Interventions Placebo Tradipitant

Updated 10 times since 2018 Last updated: Apr 23, 2024 Started: Jul 9, 2018 Primary completion: Dec 27, 2019 Completion: Dec 27, 2019

Listed as NCT03568331, this PHASE3 trial focuses on Atopic Dermatitis and remains completed. Sponsored by Vanda Pharmaceuticals, it has been updated 10 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jun 2024 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Jun 2024 [monthly]

Completed PHASE3

▶ Show 5 earlier versions

May 2020 — Jan 2021 [monthly]

Completed PHASE3

Status: Recruiting → Completed
Jul 2019 — May 2020 [monthly]

Recruiting PHASE3
Mar 2019 — Jul 2019 [monthly]

Recruiting PHASE3
Dec 2018 — Mar 2019 [monthly]

Recruiting PHASE3
Jul 2018 — Dec 2018 [monthly]

Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Vanda Pharmaceuticals

Data source: Vanda Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aventura, United States , Berlin, United States , Beverly, United States , Birmingham, United States , Boise, United States , Brighton, United States , Brooklyn, United States , Charlotte, United States , Chattanooga, United States , Cincinnati, United States and 53 more locations